News | Radiation Therapy | January 29, 2016

ASTRO Hires New Director of Scientific Affairs

Position created to increase research participation and collaboration in the field of radiation oncology

January 29, 2016 — The American Society for Radiation Oncology (ASTRO) recently welcomed Judy Keen, Ph.D., as its director of scientific affairs, a position created to grow research participation and collaboration in the field of radiation oncology.

As the ASTRO lead on scientific affairs, Keen will develop and implement initiatives that promote clinical, translational and basic radiation research, with the ultimate goal of advancing both science and evidence-based patient care throughout the radiation oncology community. Efforts involved in this push to grow research participation among radiation oncologists include managing the various funding mechanisms offered by ASTRO — such as its junior faculty awards and seed grants — as well as finding and promoting opportunities from external funding agencies to share with ASTRO members, which include nearly all practicing radiation oncologists in the United States.

Keen also will spearhead efforts to develop broader collaborations within the cancer research community, thereby responding to the growing need to eradicate the silos that can impede scientific progress. Among other roles, Keen will serve as ASTRO’s primary scientific liaison to internal and external partners involved in performing and promoting biomedical research, including the ASTRO Science Council, federal agencies, other medical societies, coalitions, the biopharmaceutical industry and policymakers.

Keen brings a wealth of diverse experience conducting and managing research projects to her new position. Prior to joining ASTRO, Keen was director of research collaborations for the National Breast Cancer Coalition (NBCC), where she led scientific oversight for multiple programs.

Before NBCC, she worked at the National Cancer Institute within the National Institutes of Health (NIH), first as a health science analyst in the Office of Science Planning and Assessment, then as program director for the NIH Genotype Tissue Expression (GTEx) project within the Biorepository and Biospecimen Research Branch. The GTEx effort included curating a collection of genomic and clinical data from more than 900 donors that was designed to explore genetic variability in humans and the changes that lead to disease.

Keen also spent several years as an assistant professor in the department of medicine at the Robert Wood Johnson Medical School at the University of Medicine and Dentistry of New Jersey, where she focused on ways to improve responses to chemotherapy in breast cancer.

Keen earned her doctorate in physiology and completed her postdoctoral training in breast cancer research at Johns Hopkins University in its Schools of Public Health and Medicine, respectively. She also earned a master of science degree in biotechnology from Hopkins and a bachelor of science degree in biology from Gettysburg College in Pennsylvania.

“Judy understands the fundamental role of research and science in helping radiation oncology teams provide the best possible care to their patients, which we can see from her extensive background both conducting research and promoting scientific activities,” said Laura Thevenot, chief executive officer of ASTRO. “I welcome her expertise and look forward to leveraging ASTRO’s position as the world’s premier radiation oncology society to further advance scientific knowledge within radiation biology and oncology.”

For more information:

Related Content

ASTRO Issues Clinical Guideline for Whole Breast Radiation Therapy
News | Radiation Therapy | March 12, 2018
The American Society for Radiation Oncology (ASTRO) today issued a new clinical guideline for the use of whole breast...
MD Anderson and RaySearch Partner to Advance Adaptive Radiation Therapy
News | Treatment Planning | February 26, 2018
The University of Texas MD Anderson Cancer Center and RaySearch Laboratories announced a new strategic alliance with...
Mirada Medical Releases DLCExpert for Radiotherapy Treatment Planning
Technology | Treatment Planning | February 22, 2018
February 22, 2018 — U.K.-based medical imaging software provider Mirada Medical has released DLCExpert, the first com
Mitchell Cancer Institute Selects RayStation for TomoTherapy Planning
News | Treatment Planning | February 16, 2018
The University of South Alabama Mitchell Cancer Institute (MCI) in Mobile, Ala., has selected RayStation as its...
Radiography Education Enrollment Shows Marginal Rise in 2017
News | Business | February 15, 2018
Directors of radiography educational programs report the number of enrolled students increased slightly in 2017, while...
Varian Acquires Mobius Medical Systems
News | Quality Assurance (QA) | February 06, 2018
February 6, 2018 – Varian announced it has acquired privately-held Mobius Medical Systems, a...
Microbubbles Make Breast Cancer More Susceptible to Radiation Therapy
News | Women's Health | February 01, 2018
February 1, 2018 – Injecting breast cancer with oxygen-filled microbubbles makes tumors three-times more sensitive to
​ITN Celebrates World Cancer Day 2018
News | Radiation Oncology | February 01, 2018
World Cancer Day takes place annually on Feb.
RayStation Selected for India’s First Proton Center
News | Proton Therapy | February 01, 2018
February 1, 2018 – Apollo Hospitals, Asia´s foremost integrated healthcare provider, has selected RayStation for a ne
Overlay Init